| abstract |
The present invention relates to porcine reproductive and respiratory syndrome virus (PRRSV) vaccines in a field of veterinary biological products, and more particularly to a PRRSV SX-105 strain having a deposit number of CGMCC No. 9906, and a use thereof in preparing PRRSV live vaccines. PRRSV SX-1 original strains are strongly pathogenic to swine. A PRRSV SX-105 attenuated strain shows safety and good immunogenicity on the swine. The PRRSV live vaccines, prepared from the PRRSV SX-105 strain, are safe and reliable, and able to generate strong immunity after immunization. The PRRSV live vaccines significantly decrease morbidity and mortality in inoculated swine groups, and have immunization effects reaching and slightly better than conventional commercial vaccines on the market, showing advantages to compete with the same kind of products around the world. The PRRSV live vaccines are capable of effectively preventing PRRS epidemic and transmission, and has broad application prospects. |